DOCSLIB.ORG

Supporting Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supporting Information Supporting Information © Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007 © Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007 Supporting Information for Identification of Protein Fold Topology Shared between Different Folds Inhibited by Natural Products Bernadette M. McArdle, Ronald J. Quinn* Table S-1 Result of data-mining for natural product inhibitors of the Zincin-like fold [a] NP/derivative NP type/ mode Inhibits Potency PDB Fold Doesn’t Inhibit Fold [41, [41] [44] [44] [45] actinonin peptide deformylase Ki = 0.28 nM 1q1y 1ix1 Peptide ACE Zincin-like 42] [41] [45] IC50 = 0.8 nM 1g2a deformylase (IC50 > 100 µM) [42] [46] Ki = 0.3 nM 1lqw [46] Ki = 0.012 -0.025 1lqy µM[43] 1lru[46] aminopeptidase P Creatinase/ 1lry[46] (3.4.11.9)[101] aminopeptidase Kis = 0.135 µM[94] no pdb glutamyl ?homology with meprin A Kii = 1.57 µM[94] ?Zincin-like aminopeptidase TET (homology with (3.4.11.7)[96] astacin) Kis = 130 µM[94] aminopeptidase W ?no pdb astacin Kii = 9500 µM[94] Zincin-like (3.4.11.16)[96] no sequence [95] IC50 = 25 nM no pdb aminopeptidase A ? [96] alanyl aminopeptidase IC50 = 2 µM ?Zincin-like (?EC) [87-91] [97] [97] (N/M) (3.4.11.2) IC50 = 0.4 µg/mL (homology with IC50 >100µg/mL LTA4H) [98] Ki = 1.4 mM arginine [99] human neutrophil IC50 = 0.3 µM Zincin-like aminopeptidase (B) ?Zincin-like [97] collagenase (MMP-8) (3.4.11.6) IC 50 > (homology with [99] IC50 = 0.19 µM 100 µg/mL LTA4H) [45] collagenase IC50 = 1 µM Zincin-like (MMP-1) [99] IC50 = 0.33 µM gelatinase B Zincin-like (MMP-9) [99] IC50 = 1.7 µM [45] stromelysin IC50 = 6 µM Zincin-like (MMP-3) [45] IC50 = 3 µM gelatinase A Zincin-like (MMP-2) [45] IC50 = 7 µM neprilysin Zincin-like strongly [92] cytosol alanyl Phosphorylase / aminopeptidase hydrolase like (3.4.11.14)[92, 93] [97] IC50 = 1 µg/mL leucine Phosphorylase / aminopeptidase hydrolase like [51] [100] (3.4.11.1) IC50 = 0.40 µg/mL no pdb glutamyl ?homology with aminopeptidase TET (3.4.11.7) [48] [48] aclacinomycin A anthracycyline bacterial IC50 = 9.9 µM CUB-like elastase ?(depends on collogenase[102] type) independent of (3.4.24.3) chelate effect ?[102] trypsin [48] Trypsin-like aclacinomycin 1q0z [47] Alpha/beta serine methylesterase hydrolase proteases (RdmC) (biosynthetic enzyme)[47] [103] [48] adriamycin anthracycyline gelatinase A Ki = 49 µM Zincin-like elastase ?(depends on (doxorubicin) (MMP-2) type) [104] [48] chelation prolidase (3.4.13.9) IC50 = 10 µM Creatinase/ trypsin Trypsin-like aminopeptidase serine proteases [48] independent of bacterial IC50 = 1.1 µM CUB-like chelate effect ?[102] collogenase[102] (3.4.24.3) bontoxilysin[49] 1i1e[49] Zincin-like [63] amastatin leucine ?IC50 = 1 µM Phosphorylase/ LTA4H Zincin-like [3] aminopeptidase hydrolase like (IC50 > 10 mM) IV(3.4.11.22) aminopeptidase P Creatinase/ [52] [52] [101, 112, 113] slow and tight leucine Ki = 30 nM Phosphorylase/ (3.4.11.9) aminopeptidase [53] [54] aminopeptidase Ki = 200 nM 1bll hydrolase like (3.4.11.1)[50, 51] arginine ?Zincin-like aminopeptidase (B) (homology with tetrahedral ?Phosphorylase/ (3.4.11.6)[114] LTA4H) [55] aminopeptidase (TET) 1y0y (no hydrolase like SCOP) (homology with picornain 2A Tryspin-like leucine (3.4.22.29) (IC50 > serine protease [ [115] aminopeptidase 0.1 mM) 55] ) cystinyl Phosphorylase/ [53] alanyl aminopeptidase Ki = 190 µM no pdb ?Zincin-like aminopeptidase hydrolase like [53, 91, [96] [106] (N/M) (3.4.11.2) IC50 = 1.5 – 2 µM (homology with (3.4.11.3) 105-107] [52] Ki = 52 nM LTA4H) [53] [116] Ki = 20 nM meprin A ?Zincin-like slow and tight[52] cystinyl (homology with aminopeptidase Phosphorylase/ astacin) [50] (3.4.11.3) hydrolase like [96] glutamyl IC50 = 1.5 – 2 µM no pdb ?homology with glutamate ?Phosphorylas/ aminopeptidase TET carboxypeptidase II hydrolase like [96, 106] [117] (3.4.11.7) (3.4.17.21) (200 (homology with µM, 88 % activity) 1cx8) [96] aminopeptidase W IC50 = 1.5 – 2 µM ?no pdb [96] (3.4.11.16) no sequence [92] cytosol alanyl strongly aminopeptidase Phosphorylase/ [92, 93] (3.4.11.14) hydrolase like aminopeptidase Y 0.02 mM, 10% no pdb ?Zincin-like [108] [108] (3.4.11.15) activity (homology with LTA4H) [52] [52] slow and tight bacterial leucyl Ki = 0.26 nM Phosphorylase/ aminopeptidase hydrolase like (3.4.11.10) [111] pyroglutamyl IC50 = 1 µg/ml Phosphorylase/ aminopeptidase hydrolase like (3.4.19.3) mitochondrial No pdb ?Zincin-like intermediate peptidase (homology with (3.4.24.59)[109] neurolysin) X-his dipeptidase No pdb ?Phosphorylase (3.4.13.3)[110] /hydrolase like (homology with peptidase T) [118] ancovenin ACE IC50 = 0.87 µM Zincin-like [119] [119] [119] antibiotic A 58365A competitive ACE IC50 = 0.0018 µM Zincin-like [119] [119] [119] antibiotic A 58365B competitive ACE IC50 = 0.004 µM Zincin-like [119] [120] [119] antibiotic I5B1/K4 non-competitive ACE Ki = 0.18 µM Zincin-like Trypsin Trypsin-like serine protease carboxypeptidase A Weak 2,3%[119] Phosphorylase/ hydroalse Carboxypeptidase Phosphorylase/ B[119] hydrolase [119] [119, 121] antibiotic I5B2 competitive ACE IC50 = 0.091 µM Zincin-like [119] [122] [122] antibiotic K 13 non-competitive ACE Ki = 0.349 µM Zincin-like trypsin Trypsin-like serine protease leucine 6 % inhibition[122] Phosphorylase/ aminopeptidase hydrolase like carboxypeptidase Phosphorylase/ A [122] hydrolase aminopeptidas B 5,3 % inhibition[122] ?Zincin-like or phosphorylase/ hydrolase like [119] [119] [119] antibiotic K 26 non-competitive ACE Ki = 0.03 µM Zincin-like trypsin Trypsin-like [123] IC50 = 6.7 ng/ml serine protease papain[119] carboxypeptidase A 13,7 % inhibition[123] Phosphorylase/ Cysteine hydrolase like proteinase carboxypeptidase B[119] Phosphorylase/ hydrolase leucine aminopeptidase[119] Phosphorylase/ hydrolase thermolysin[119] Zincin-like chymostrypsin[119] ?Zincin-like or phosphorylase/ hydrolase antipain MEP (3.4.24.20) weak[165] Zincin-like serralysin[124] Zincin-like cytosol alanyl 0.1 mM, 39 % Phosphorylase/ aminopeptidase inhibition[93] hydrolase like (3.4.11.14) aminopeptidase Y 0.05 mg/ml, 19 % no pdb ?Zincin-like (3.4.11.15)[125] inhibition[125] (homology with LTA4H) alanyl aminopeptidase 0.1 mM, 47 % no pdb ?Zincin-like (N/M) (3.4.11.2)[107] inhibition[107] (homology with LTA4H) aminopeptidase P Creatinase/ (3.4.11.9)[126] aminopeptidase arginine no pdb ?Zincin-like aminopeptidase (B) (homology with (3.4.11.6)[127] LTA4H) tissue kallkrein No pdb/no (3.4.21.B47)[128] sequence renal tissue kallikrein Trypsin-like (3.4.21.35)[128] serine protease plasma kallikrein Trypsin-like (3.4.21.34)[129, 130] serine protease chymase partial[166] Trypsin-like (3.4.21.39)[131] serine protease 0.01 mM, 94 % Trypsin-like tryptase (3.4.21.59)[131, inhibition[167] serine protease 132] slight[168] Trypsin-like lysyl endopeptidase serine protease (3.4.21.50) [169] IC50 = 43 nM Trypsin-like u-plasminogenactivator serine protease (3.4.21.73) Trypsin-like granzyme B serine protease (3.4.21.79)[133] Trypsin-like enteropeptidase serine protease (3.4.21.9)[134] [115] IC50 = 0.065 mM Trypsin-like picornain 2A serine protease (3.4.22.29)[135] Cysteine dipeptidyl proteinase aminopeptidase (3.4.14.1)[136, 137] 1 µM, 93 % Cysteine cathepsin B inhibition[170] proteinase (3.4.22.1)[138-148] strongly [149] Cysteine cathepsin L proteinase (3.4.22.15)[149-151] 0.1 mM, 91 % Cysteine cathepsin H inhibition[152] proteinase (3.4.22.16)[152] 0.01 mM, 53 % inhibition[171] Cysteine proteinase papain (3.4.22.2)[153] 0.05 µM, complete ?Cysteine V-cath endopeptidase inhibition[154] proteinase (3.4.22.50)[154] (homology with cathepsin F) 0.01 mM, 80 – 90 % No pdb Cysteine calpain-1 inhibition[155] proteinase (3.4.22.52)[155] 0.01 mM, 80 - 90 % Cysteine calpain-2 inhibition[155] proteinase (3.4.22.53)[156, 157] 0.02 mM, 82 – 87 % [172] loss of activity 0.05 mM, complete [173] inhibition [174] Ki = 2.06 µM Subtilisin-like subtilisin (3.4.21.62)[158] Subtilisin-like thermitase (3.4.21.66)[159] moderately [160] Subtilisin-like furin (3.4.21.75) [160, 161] 1 mM, 35.9 - 45.7 % activity[175] 1bcr[56] Alpha/beta carboxypeptidase D hydrolase (3.4.16.6)[56] no pdb ?Phosphorylase tripeptidase /hydrolase like aminopeptidase (homology with (3.4.11.4)[162] Peptidase T) no pdb ?Alpha/beta oligopeptidase B hydrolase (3.4.21.83)[163, 164] (homology with prolyloligopeptid ase) [48] [48] aranciamycin anthracycline bacterial collagenase IC50 = 0.37 µM CUB-like elastase ?(depends on (3.4.24.3) type) trypsin[48] Trypsin-like serine proteases [178] arphamenine A arginine IC50 = 0.007 µg/mL No pdb ?Zincin-like leucine ? [178] aminopeptidase (B) IC50 = 0.005 µg/mL (homology with aminopeptidase [176] [179] (3.4.11.6) Ki = 2.5 nM LTA4H) (EC.?) carboxypeptidase A [177] Phosphorylase/ aminopeptidase A ? (inhibited by hydrolase like (EC. ?) derivatives) alanyl aminopeptidase 0.5 mM, 42 % no pdb ?Zincin-like (N/M) (3.4.11.2)[91] inhibition[91] (homology with LTA4H) cystinyl Phosphorylase/ aminopeptidase hydrolase like (3.4.11.3)[50] leucine Phosphorylase/ aminopeptidase hydrolase like (3.4.11.1)[50] dipeptidyl No pdb aminopeptidase No sequence (3.4.14.4)[176] match ACE[176] Zincin-like carboxypeptidase No pdb ?Zincin-like (3.4.17.19)[176] (homology search) cytosol alanyl 0.1 mM, 80 % Phosphorylase/ aminopeptidase inhibition[93] hydrolase like (3.4.11.14) [179] arphamenine B arginine Ki = 0.84 nM No pdb ?Zincin-like leucine ? aminopeptidase (B) (homology with aminopeptidase (3.4.11.6)[87] LTA4H) (EC.?) ? carboxypeptidase A [177] Phosphorylase/ aminopeptidase A (inhibited by hydrolase like (EC.
Load more

Recommended publications
  • THESIS Entitled Studies on Fraction 1 Protein of Beta Vulgaris Submitted for the Degree of DOCTOR of PHILOSOPHY by Kenneth Edwar
    THESIS entitled Studies on Fraction 1 Protein of Beta vulgaris Submitted for the degree of DOCTOR OF PHILOSOPHY by Kenneth Edward Moon 1 970 TABLE OF CONTENTS Acknowledgements i Abbreviations i Summary ii Chapter 1 Introduction 1.1 Carbon Dioxide Fixation in the Calvin • 1 Cycle 1.2 Some Properties of RuDPcase and Similarity 2 to Fraction 1 Protein 1.3 Cellular Location of Fraction 1 Protein 3 1.4 The Mechanism of Action of RuDPcase 4 1.5 Structure of Fraction 1 Protein from 13 Higher Plants 1.6 Relationship of Structure to Enzymic 14 Activity and Role of Sulphydryl Groups 1.7 Studies on RuDPcase from Sources other 17 than the Higher Plants 1.8 Comparison of Some Kinetic and Physical 21 Constants of RuDPcase from Different Sources 1.9 Aim of This Research Project 23 Chapter 2 Methods and Materials 2.1 Plant Material 24 2.2 Preparation of Chloroplasts and Isolation 24 of Fraction 1 Protein 2.3 Concentrating Protein Solutions 26 2.4 Preparation of Reduced and Carboxy- 27 methylated Fraction 1 Protein 2.5 Preparation of Maleyl-carboxymethyl 28 Fraction 1 Protein 2.6 Removal of Maleyl Groups 29 2.7 Gel Electrophoresis 30 2.7 (i) Polyacrylamide Disk Electrophoresis 30 (ii) Polyacrylamide Electrophoresis in 31 the presence of SDS (iii) Slab Acrylamide Gel Electrophoresis 32 (iv) Isoelectric Focusing 33 2.8 Ribulose-1,5-diphosphate Carboxylase 3^ Assay 2.9 Preparation of the S-Sulphenylsulphanate 34 Derivative of Fraction 1 Protein 2.10 Edman Degradations 35 2.11 Hydrazinolysis 35 2.12 Isolation of Blocked N-Terminal Peptides 36 2.13 Tryptic
    [Show full text]
  • Cellular Localization of Tissue Kallikrein and Kallistatin Mrnas in Human
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 48 (1995),pp. 690—697 Cellularlocalization of tissue kallikrein and kallistatin mRNAs in human kidney LI-MET CHEN, QING SONG, LEE CHAO, and JULIE CHAO Department of Biochemistty and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA Cellular localization of tissue kallikrein and kallistatin mRNAs in kidney, tissue kallikrein is localized at the following sites: reab- human kidney. The renal kallikrein-kinin system has been implicated in sorption droplets of the proximal and distal tubules [6], renal the regulation of blood pressure and sodium/water excretion. The activity of renal kallikrein is controlled by a number of factors in vivo. Kallistatin interstitium [7], connecting tubule cells [8] and collecting ducts is a newly identified serine proteinase inhibitor (serpin) which binds to [9]. Also, Vio, Figueroa and Caorsi [10] reported that tissue tissue kallikrein and inhibits its enzymatic activity in vitro. To understand kallikrein is localized in the connecting tubules, but not in the the role of kallistatin in modulating tissue kallikrein's function in vivo, we proximal tubules. Immunoreactive low molecular weight kinino- examined the anatomical relationship between human tissue kallikrein and kallistatin in the kidney by in situ hybridization histochemistry. Tissue gen has been localized in the distal tubules and collecting ducts of kallikrein and kallistatin gene transcripts were identified using digoxige- human kidney [8, 11]. Anatomical co-localization of kallikrein and nm-labeled riboprobes at the cellular level. Antisense and sense ribo- the substrate kininogen in the kidney provides the basis for a probes corresponding to the 3' region of the human kallikrein andfunctional role of intrarenal kinins in the regulation of blood kallistatin mRNAs were synthesized by in vitro transcription and used for hybridization.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Supplemental Methods
    Supplemental Methods: Sample Collection Duplicate surface samples were collected from the Amazon River plume aboard the R/V Knorr in June 2010 (4 52.71’N, 51 21.59’W) during a period of high river discharge. The collection site (Station 10, 4° 52.71’N, 51° 21.59’W; S = 21.0; T = 29.6°C), located ~ 500 Km to the north of the Amazon River mouth, was characterized by the presence of coastal diatoms in the top 8 m of the water column. Sampling was conducted between 0700 and 0900 local time by gently impeller pumping (modified Rule 1800 submersible sump pump) surface water through 10 m of tygon tubing (3 cm) to the ship's deck where it then flowed through a 156 µm mesh into 20 L carboys. In the lab, cells were partitioned into two size fractions by sequential filtration (using a Masterflex peristaltic pump) of the pre-filtered seawater through a 2.0 µm pore-size, 142 mm diameter polycarbonate (PCTE) membrane filter (Sterlitech Corporation, Kent, CWA) and a 0.22 µm pore-size, 142 mm diameter Supor membrane filter (Pall, Port Washington, NY). Metagenomic and non-selective metatranscriptomic analyses were conducted on both pore-size filters; poly(A)-selected (eukaryote-dominated) metatranscriptomic analyses were conducted only on the larger pore-size filter (2.0 µm pore-size). All filters were immediately submerged in RNAlater (Applied Biosystems, Austin, TX) in sterile 50 mL conical tubes, incubated at room temperature overnight and then stored at -80oC until extraction. Filtration and stabilization of each sample was completed within 30 min of water collection.
    [Show full text]
  • A Novel, Low Power Biosensor for Real Time Monitoring of Creatinine and Urea in Peritoneal Dialysis
    A Novel, Low Power Biosensor for Real Time Monitoring of Creatinine and Urea in Peritoneal Dialysis Bhusana Premanode*, Chris Toumazou** *Department of Bioengineering, Imperial College, London, UK **The Institute of Biomedical Engineering, Imperial College, London, UK ABSTRACT based on the immobilization of urease or creatinase onto the surface of the gate insulator [1]. Novel biosensors, based on immobilized creatininase, The FET-based potentiometric biosensors of creatinine creatinase and urease are developed, using ISFETs with have several disadvantages namely, that there is interference weak inversion at pH 6-8 and 37.0oC. The ISFETs with due to ammonia and other ionic substances [1]. Another circuitry, demonstrate a linear relationship of urea and major drawback is that the response is very non-linear, creatinine at the range of 0-200 mM and 0-20 mM, caused by the fact that the induced changes in pH and respectively. Preliminary results show that biosensors temperature decrease the enzyme activity and stability operating in weak inversion mode can eliminate many of the drastically [2]. Moreover, the devices generate undesired disadvantages of ISFETs operating in the strong inversion extra coulomb charges. region, providing a wide dynamic range output in nanoAmp. Such characteristics fit the analytical requirements for 2 THEORETICAL CONSIDERATIONS improving real-time monitoring in Peritoneal Dialysis (PD). Further work covers stability of ISFET sensors biased with 2.1 Chemical Reactions of Creatinine and Urea CMOS circuits in the weak inversion mode working in the room temperature of 15°C to 40°C. Creatinine and urea are important for diagnosis of renal, thyroid and muscle dysfunctions.
    [Show full text]
  • B Number Gene Name Mrna Intensity Mrna
    sample) total list predicted B number Gene name assignment mRNA present mRNA intensity Gene description Protein detected - Membrane protein membrane sample detected (total list) Proteins detected - Functional category # of tryptic peptides # of tryptic peptides # of tryptic peptides detected (membrane b0002 thrA 13624 P 39 P 18 P(m) 2 aspartokinase I, homoserine dehydrogenase I Metabolism of small molecules b0003 thrB 6781 P 9 P 3 0 homoserine kinase Metabolism of small molecules b0004 thrC 15039 P 18 P 10 0 threonine synthase Metabolism of small molecules b0008 talB 20561 P 20 P 13 0 transaldolase B Metabolism of small molecules chaperone Hsp70; DNA biosynthesis; autoregulated heat shock b0014 dnaK 13283 P 32 P 23 0 proteins Cell processes b0015 dnaJ 4492 P 13 P 4 P(m) 1 chaperone with DnaK; heat shock protein Cell processes b0029 lytB 1331 P 16 P 2 0 control of stringent response; involved in penicillin tolerance Global functions b0032 carA 9312 P 14 P 8 0 carbamoyl-phosphate synthetase, glutamine (small) subunit Metabolism of small molecules b0033 carB 7656 P 48 P 17 0 carbamoyl-phosphate synthase large subunit Metabolism of small molecules b0048 folA 1588 P 7 P 1 0 dihydrofolate reductase type I; trimethoprim resistance Metabolism of small molecules peptidyl-prolyl cis-trans isomerase (PPIase), involved in maturation of b0053 surA 3825 P 19 P 4 P(m) 1 GenProt outer membrane proteins (1st module) Cell processes b0054 imp 2737 P 42 P 5 P(m) 5 GenProt organic solvent tolerance Cell processes b0071 leuD 4770 P 10 P 9 0 isopropylmalate
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier Et Al
    US 200601 10747A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier et al. (43) Pub. Date: May 25, 2006 (54) PROCESS FOR IMPROVED PROTEIN (60) Provisional application No. 60/591489, filed on Jul. EXPRESSION BY STRAIN ENGINEERING 26, 2004. (75) Inventors: Thomas M. Ramseier, Poway, CA Publication Classification (US); Hongfan Jin, San Diego, CA (51) Int. Cl. (US); Charles H. Squires, Poway, CA CI2O I/68 (2006.01) (US) GOIN 33/53 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: (52) U.S. Cl. ................................ 435/6: 435/7.1; 435/471 KING & SPALDING LLP 118O PEACHTREE STREET (57) ABSTRACT ATLANTA, GA 30309 (US) This invention is a process for improving the production levels of recombinant proteins or peptides or improving the (73) Assignee: Dow Global Technologies Inc., Midland, level of active recombinant proteins or peptides expressed in MI (US) host cells. The invention is a process of comparing two genetic profiles of a cell that expresses a recombinant (21) Appl. No.: 11/189,375 protein and modifying the cell to change the expression of a gene product that is upregulated in response to the recom (22) Filed: Jul. 26, 2005 binant protein expression. The process can improve protein production or can improve protein quality, for example, by Related U.S. Application Data increasing solubility of a recombinant protein. Patent Application Publication May 25, 2006 Sheet 1 of 15 US 2006/0110747 A1 Figure 1 09 010909070£020\,0 10°0 Patent Application Publication May 25, 2006 Sheet 2 of 15 US 2006/0110747 A1 Figure 2 Ester sers Custer || || || || || HH-I-H 1 H4 s a cisiers TT closers | | | | | | Ya S T RXFO 1961.
    [Show full text]
  • Protein Digestibility of Cereal Products
    foods Communication Protein Digestibility of Cereal Products Iris Joye Department of Food Science, University of Guelph, Guelph, ON N1G 2W1, Canada; [email protected]; Tel.: +1-519-824-4120 (ext. 52470) Received: 5 May 2019; Accepted: 3 June 2019; Published: 8 June 2019 Abstract: Protein digestibility is currently a hot research topic and is of big interest to the food industry. Different scoring methods have been developed to describe protein quality. Cereal protein scores are typically low due to a suboptimal amino acid profile and low protein digestibility. Protein digestibility is a result of both external and internal factors. Examples of external factors are physical inaccessibility due to entrapment in e.g., intact cell structures and the presence of antinutritional factors. The main internal factors are the amino acid sequence of the proteins and protein folding and crosslinking. Processing of food is generally designed to increase the overall digestibility through affecting these external and internal factors. However, with proteins, processing may eventually also lead to a decrease in digestibility. In this review, protein digestion and digestibility are discussed with emphasis on the proteins of (pseudo)cereals. Keywords: protein digestibility; cereals; pseudocereals; processing; antinutritional factors 1. Introduction Proteins are abundantly present in all living cells, and as such are a vital part of our diet. In order to be usable to the human body after ingestion, dietary proteins have to be hydrolysed into their basic building blocks, i.e., amino acids or small peptides. Hereto, the human gastrointestinal tract possesses an assortment of protein hydrolysing enzymes or peptidases. The physiological roles of proteins are very diverse and range from functioning as pure nitrogen storage molecules over delivering structure building capacity to catalysing a myriad of reactions as metabolically active enzymes or serving as transporter vehicles for poorly soluble or physiologically unstable components [1].
    [Show full text]
  • Downloaded from Mage and Compared
    bioRxiv preprint doi: https://doi.org/10.1101/527234; this version posted January 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Characterization of a thaumarchaeal symbiont that drives incomplete nitrification in the tropical sponge Ianthella basta Florian U. Moeller1, Nicole S. Webster2,3, Craig W. Herbold1, Faris Behnam1, Daryl Domman1, 5 Mads Albertsen4, Maria Mooshammer1, Stephanie Markert5,8, Dmitrij Turaev6, Dörte Becher7, Thomas Rattei6, Thomas Schweder5,8, Andreas Richter9, Margarete Watzka9, Per Halkjaer Nielsen4, and Michael Wagner1,* 1Division of Microbial Ecology, Department of Microbiology and Ecosystem Science, University of Vienna, 10 Austria. 2Australian Institute of Marine Science, Townsville, Queensland, Australia. 3 Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, University of 15 Queensland, St Lucia, QLD, Australia 4Center for Microbial Communities, Department of Chemistry and Bioscience, Aalborg University, 9220 Aalborg, Denmark. 20 5Institute of Marine Biotechnology e.V., Greifswald, Germany 6Division of Computational Systems Biology, Department of Microbiology and Ecosystem Science, University of Vienna, Austria. 25 7Institute of Microbiology, Microbial Proteomics, University of Greifswald, Greifswald, Germany 8Institute of Pharmacy, Pharmaceutical Biotechnology, University of Greifswald, Greifswald, Germany 9Division of Terrestrial Ecosystem Research, Department of Microbiology and Ecosystem Science, 30 University of Vienna, Austria. *Corresponding author: Michael Wagner, Department of Microbiology and Ecosystem Science, Althanstrasse 14, University of Vienna, 1090 Vienna, Austria. Email: wagner@microbial- ecology.net 1 bioRxiv preprint doi: https://doi.org/10.1101/527234; this version posted January 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Chemical Transformations Encoded by a Gene Cluster in Streptomyces Coelicolor Containing an Unusual Gtp Cyclohydrolase
    Chemical Transformations Encoded by a Streptomyces coelicolor Gene Cluster with an Unusual GTP Cyclohydrolase Item Type text; Electronic Dissertation Authors Spoonamore, James Edward Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 11/10/2021 06:44:52 Link to Item http://hdl.handle.net/10150/194825 CHEMICAL TRANSFORMATIONS ENCODED BY A GENE CLUSTER IN STREPTOMYCES COELICOLOR CONTAINING AN UNUSUAL GTP CYCLOHYDROLASE by James Edward Spoonamore ______________________________ A Dissertation Submitted to the Faculty of the DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOPHYSICS In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2008 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Dissertation Committee, we certify that we have read the dissertation prepared by James Edward Spoonamore entitled Chemical Transformations Encoded by a Gene Cluster in Streptomyces coelicolor Containing an Unusual GTP Cyclohydrolase and recommend that it be accepted as fulfilling the dissertation requirement for the Degree of Doctor of Philosophy _______________________________________________________________________ Date: April 16, 2008 Vahe Bandarian _______________________________________________________________________
    [Show full text]
  • Durham E-Theses
    Durham E-Theses Midgut proteases from larval spodoptera littoralis (lepidoptera: noctutoae) Lee, Michael James How to cite: Lee, Michael James (1992) Midgut proteases from larval spodoptera littoralis (lepidoptera: noctutoae), Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/5739/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk MIDGUT PROTEASES FROM LARVAL SPODOPTERA LITTORALIS (LEPIDOPTERA: NOCTUTOAE) By Michael James Lee B.Sc. (Dunelm) The copyright of this thesis rests with the author. No quotation from it should be pubhshed without his prior written consent and information derived from it should be acknowledged. Being a thesis submitted for the degree of Doctor of Philosophy of the University of Durham. November, 1992 Hatfield College University of Durham 6 APR 1993 DECLARATION I hereby declare that the work presented in this document is based on research carried out by me, and that no part has been previously submitted for a degree in this or any other university.
    [Show full text]